AIDS Therapy

Vaccines and low daily doses of interleukin 2 may hold key to cure

Published in Vaccine Weekly, April 3rd, 2002

A new clinical trial testing an HIV vaccine together with low daily doses of interleukin 2 (IL2) - led by Dr. Kendall Smith, chief of immunology in the department of medicine at Weill Cornell Medical College - is designed to determine whether it is possible to achieve control of HIV by enhancing the body's immunity to the virus.

Smith's team has previously shown that low daily doses of the T cell growth factor IL2 can result in accelerated improvement of the immune system when given to individuals with chronic HIV infection. Now, the team is testing whether it is possible to generate protective immunity to HIV, so that antiviral drugs will no longer be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry